Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
1.250
+0.060 (5.04%)
At close: Jun 26, 2026, 4:00 PM EDT
1.280
+0.030 (2.40%)
Pre-market: Jun 29, 2026, 7:54 AM EDT
Metagenomi Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Metagenomi Therapeutics stock have an average target of 8.00, with a low estimate of 7.00 and a high estimate of 9.00. The average target predicts an increase of 540.00% from the current stock price of 1.25.
Analyst Consensus: Buy
* Price targets were last updated on May 13, 2026.
Analyst Ratings
The average analyst rating for Metagenomi Therapeutics stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Buy Reiterates $7 | Buy | Reiterates | $7 | +460.00% | May 13, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $12 → $9 | Buy | Maintains | $12 → $9 | +620.00% | May 12, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 11, 2026 |
Financial Forecast
Revenue This Year
12.15M
from 25.21M
Decreased by -51.81%
Revenue Next Year
12.52M
from 12.15M
Increased by 3.09%
EPS This Year
-2.11
from -2.36
EPS Next Year
-1.47
from -2.11
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 18.7M | 20.0M | |
| Avg | 12.1M | 12.5M | |
| Low | 5.0M | 5.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -25.8% | 64.6% | |
| Avg | -51.8% | 3.1% | |
| Low | -80.2% | -58.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | -2.11 | -1.47 | |
| Low | - | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.